Is ADDXF or NOBL a better dividend investment in 2026?

ADDXF currently yields 202.02% with a 5% 5-year dividend growth rate. NOBL yields 4.00% with 5% growth. The better choice depends on your goal: ADDXF offers higher current income.

What is the dividend yield difference between ADDXF and NOBL?

ADDXF has a forward dividend yield of 202.02% ($2.00/share annually). NOBL yields 4.00% ($2.00/share annually). The yield gap is 198.02 percentage points.

Home › Compare › ADDXF vs NOBL

ADDXF vs NOBL: Dividend Comparison 2026

ADDXF yields 202.02% · NOBL yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ADDXF wins by $126.50M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ADDXF

● Live price

202.02%

Share price

$0.99

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$126.53M

Annual income

$64,106,411.82

Full ADDXF calculator →

NOBL

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full NOBL calculator →

Portfolio growth — ADDXF vs NOBL

📍 ADDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ADDXF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ADDXF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ADDXF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADDXF

Annual income on $10K today (after 15% tax)

$17,171.72/yr

After 10yr DRIP, annual income (after tax)

$54,490,450.05/yr

NOBL

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, ADDXF beats the other by $54,489,685.74/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADDXF + NOBL for your $10,000?

ADDXF: 50%NOBL: 50%

100% NOBL50/50100% ADDXF

Portfolio after 10yr

$63.28M

Annual income

$32,053,655.51/yr

Blended yield

50.65%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADDXF buys

NOBL buys

No recent congressional trades found for ADDXF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricADDXFNOBL

Forward yield	202.02% ✓	4.00%
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$126.53M ✓	$28.0K
Annual income after 10y	$64,106,411.82 ✓	$899.19
Total dividends collected	$119.31M ✓	$6.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ADDXF vs NOBL ($10,000, DRIP)

Year	ADDXF Portfolio	ADDXF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$30,902	$20,202.02	$11,120	$420.00	+$19.8K → ADDXF
2	$91,409	$58,344.23	$12,357	$458.31	+$79.1K → ADDXF
3	$259,102	$161,293.94	$13,721	$499.76	+$245.4K → ADDXF
4	$704,521	$427,281.62	$15,227	$544.58	+$689.3K → ADDXF
5	$1,839,646	$1,085,809.10	$16,885	$593.02	+$1.82M → ADDXF
6	$4,618,204	$2,649,782.60	$18,713	$645.34	+$4.60M → ADDXF
7	$11,158,255	$6,216,776.60	$20,724	$701.81	+$11.14M → ADDXF
8	$25,977,314	$14,037,980.69	$22,938	$762.73	+$25.95M → ADDXF
9	$58,339,227	$30,543,501.04	$25,372	$828.41	+$58.31M → ADDXF
10	$126,529,384	$64,106,411.82	$28,047	$899.19	+$126.50M → ADDXF

ADDXF vs NOBL: Complete Analysis 2026

ADDXF — Stock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Full ADDXF Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →

📬

Get this ADDXF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADDXF vs SCHD ADDXF vs JEPI ADDXF vs O ADDXF vs KO ADDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.